A late-stage trial testing Novartis’ Cosentyx in individuals with giant cell arteritis failed to meet its primary endpoint. The phase 3 study tested Cosentyx alongside a 26-week steroid taper and ...

Novartis fails in late-stage trial for Cosentyx in giant cell arteritis Jul. 03, 2025 7:06 AM ET Novartis AG (NVS) Stock, NVSEF Stock By: Dulan Lokuwithana, SA News Editor Play (1min) ...

Novartis ( NYSE: NVS) on Tuesday said that Coartem (artemether-lumefantrine) Baby has been approved by Swissmedic as the ...

It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete ...

Cosentyx belongs to a newer class of drugs that inhibit IL-17, and Novartis is aiming to encourage doctors to use it with longer term data showing that its benefits persist after five years, as ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial Congress Is Buying Into UnitedHealth's 46% Crash — What Do They Know That Wall Street Doesn't? 1 day ago ...

The loss of special government employee status for four members of the CDC’s Advisory Committee on Immunization Practices follows the resignation of ACIP co-lead Lakshmi Panagiotakopoulos, who left in ...

AstraZeneca put down $110 million upfront to partner with China’s CSPC Pharmaceutical, aiming to leverage AI to develop novel oral therapies for a wide variety of chronic diseases, in a deal announced ...